What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Radiation therapy
His primary areas of study are Radiation therapy, Internal medicine, Oncology, Pathology and Surgery. Jens Overgaard has researched Radiation therapy in several fields, including Breast cancer, Carcinoma and Nuclear medicine. His study looks at the relationship between Breast cancer and fields such as Chemotherapy, as well as how they intersect with chemical problems.
His work in Internal medicine tackles topics such as Gastroenterology which are related to areas like Colorectal cancer and Adenoid cystic carcinoma. His work carried out in the field of Oncology brings together such families of science as Odds ratio, Cell, Clinical trial, Randomized controlled trial and Hazard ratio. Jens Overgaard has included themes like Cancer research, Radiosensitivity, Hypoxia, Hyperthermia and In vivo in his Pathology study.
His most cited work include:
- Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy (2148 citations)
- Postoperative radiotherapy in high-risk postmenopausal breast- cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial (1303 citations)
- Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck (874 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Radiation therapy, Oncology, Pathology and Surgery. His work on Endocrinology expands to the thematically related Internal medicine. Jens Overgaard combines subjects such as Carcinoma, Randomized controlled trial and Nuclear medicine with his study of Radiation therapy.
The study incorporates disciplines such as Head and neck squamous-cell carcinoma, Head and neck, Basal cell, Hazard ratio and Cohort in addition to Oncology. His study looks at the intersection of Pathology and topics like In vivo with Mammary carcinoma. His Surgery study frequently draws connections to adjacent fields such as Urology.
He most often published in these fields:
- Internal medicine (40.05%)
- Radiation therapy (35.35%)
- Oncology (30.55%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (40.05%)
- Oncology (30.55%)
- Radiation therapy (35.35%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Radiation therapy, Head and neck cancer and DAHANCA. His study in Internal medicine concentrates on Cancer, Breast cancer, Cohort, Head and neck squamous-cell carcinoma and Nimorazole. His studies deal with areas such as Carcinoma, Clinical endpoint, Randomized controlled trial, Pathology and Hazard ratio as well as Oncology.
The Radiation therapy study combines topics in areas such as Clinical trial, Cohort study and Hypoxia. His DAHANCA study combines topics in areas such as Dose fractionation, Head and neck, Logistic regression and Quality assurance. His work on Prospective cohort study as part of his general Surgery study is frequently connected to In patient, thereby bridging the divide between different branches of science.
Between 2014 and 2021, his most popular works were:
- Radiation oncology in the era of precision medicine (343 citations)
- DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer (223 citations)
- The impact of hypoxia and its modification of the outcome of radiotherapy. (125 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Radiation therapy
His primary scientific interests are in Internal medicine, Radiation therapy, Oncology, DAHANCA and Head and neck cancer. Much of his study explores Internal medicine relationship to Surgery. His biological study spans a wide range of topics, including Absolute risk reduction, Clinical trial, Medical physics and Carcinoma.
His Oncology study integrates concerns from other disciplines, such as Head and neck squamous-cell carcinoma, Pathology, Clinical endpoint, Hazard ratio and Breast cancer. His DAHANCA research is multidisciplinary, incorporating elements of Glottic Squamous Cell Carcinoma, Laryngectomy and Nimorazole. His Head and neck cancer research is multidisciplinary, incorporating perspectives in Prospective data, Larynx and Quality assurance.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
